Insight

Dec 30, 2024, 10:54

Raul Cordoba: Early progression beyond first-line chemoimmunotherapy in follicular lymphoma by Alberto Bavieri et al.

Raul Cordoba, Chair of Community Stakeholder Committee at European Hematology Association (EHA) and Coordinator of the Lymphoma Unit, shared a post on X:

“Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study – Bavieri – 2024.”

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Authors: Alberto Bavieri et al.

Raul cordoba

Raúl Córdoba Mascuñano, MD, PhD is a specialist in hematology and hemotherapy. He is the Chair of Community Stakeholder Committee at European Hematology Association (EHA) and Coordinator of the Lymphoma Unit and Associate Chief of Hematology Department at Jiménez Díaz Foundation.

He is the principal investigator for numerous clinical trials for non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia and other chronic lymphoproliferative syndromes. He is a member of the ethical review board at his current workplace.

Alberto Bavieri Alessandra Tucci Alessia Bari Annalisa Arcari Antonella Anastasia Antonino Neri Benedetta Bianchi Clara Mannarella Federica Cavallo Fortunato Morabito Gloria M. Casaluci Jacopo Olivieri Maggi Alessandro Mansueto G. Rosaria Maria E. Nizzoli Massimo Gentile Michele Cimminiello Nicola Di Renzo Ombretta Annibali Stefano Luminari Vicenzo Pavone Vittoria Tarantino Vittorio R. Zilioli

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial